After-Hours Stock Movers 6/8: (M) (CFRX) (SMG) HIGHER; (SLNO) (CHK) (CERC) LOWER (more...)

After-Hours Movers:

Soleno Therapeutics, Inc. (NASDAQ: SLNO) 49% LOWER; announced top-line results from the Companys Phase III trial, DESTINY PWS (C601), evaluating once-daily Diazoxide Choline Controlled Release (DCCR) tablets for patients with Prader-Willi Syndrome (PWS). The study did not meet its primary endpoint of change from baseline in hyperphagia. The change was measured by the total score of a Hyperphagia Questionnaire for Clinical Trials (HQ-CT, 036). An improvement in HQ-CT is represented by a decrease in the score. The mean (SE) change from baseline for DCCR was -5.94 (0.879) and for placebo was -4.27 (1.145). The least squares mean difference in HQ-CT score of DCCR compared with placebo was -1.67 (1.294); 95% confidence interval (-4.24, 0.89); p=0.1983.

Chesapeake Energy (NYSE: CHK) 14.4% LOWER; Said to Prepare Chapter 11 Filing, Giving Lenders Control - Bloomberg

Cerecor Inc. (Nasdaq: CERC) 14% LOWER; intends to offer for sale shares of its common stock in an underwritten public offering.

Macy's (NYSE: M) 9% HIGHER; Announcing $4.5 Billion in Financing

ContraFect Corp. (NASDAQ: CFRX) 5.6% HIGHER; Cantor Fitzgerald initiates coverage onwith a Overweight rating and a price target of $15.00.

Stitch Fix (NASDAQ: SFIX) 4.7% LOWER; reported Q3 EPS of ($0.33), $0.17 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $371.7 million versus the consensus estimate of $406.66 million.

Coupa Software (NASDAQ: COUP) 4.4% LOWER; reported Q1 EPS of $0.20, $0.13 better than the analyst estimate of $0.07. Revenue for the quarter came in at $119.2 million versus the consensus estimate of $111.51 million.

The Scotts Miracle-Gro Company (NYSE: SMG) 4% HIGHER; announced increased sales and earnings guidance based on higher demand in both its U.S. Consumer and Hawthorne segments.

Retrophin, Inc. (NASDAQ: RTRX) 3.3% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering, subject to market and other conditions.

Casey's General Stores (NASDAQ: CASY) 2.7% LOWER; reported Q4 EPS of $1.67, $0.12 worse than the analyst estimate of $1.79. Revenue for the quarter came in at $1.81 billion versus the consensus estimate of $1.76 billion. Fiscal 2021 Guidance - Due to the continued uncertainty of COVID-19, guidance for the fiscal year ending April 30, 2021 will not be provided at this time. This will be reevaluated as conditions warrant.

Mesa Laboratories, Inc. (NASDAQ: MLAB) 2.4% LOWER; announced that it has commenced an underwritten public offering of $100 million of shares of its common stock

Extreme Networks (NASDAQ: EXTR) 2.1% HIGHER; Director, John Shoemaker, bought 50,000 shares on 06/05 at $5.11.

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) 1.7% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the companys first-in-class pyruvate kinase-R (PKR) activator mitapivat for the treatment of patients with thalassemia. Mitapivat is an investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated PKR enzymes.

You May Also Be Interested In

• After-hours movers: Meta, Ford, IBM, ServiceNow and more
• Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
• Avantor (AVTR) Tops Q1 EPS by 2c